1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
I-SCREEN (Improving Strategies for Cancer Reduction through Early-detection and ENgagement) is sponsored by National Cancer Institute (NCI). This program, involving the University of Colorado Cancer Center, focuses on evaluating the benefits and harms of new cancer screening technologies and their impacts on a representative sample of the U. S.
population.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Summarized from a third-party grants-portal listing rather than the funder's own page. Confirm details with the funder before applying.
Funded Early Detection and Screening Grants | Division of Cancer Prevention Funded Early Detection and Screening Grants Active Grants Completed Grants Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma University Of Colorado Denver Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN) Elyse LeeVan, M. D. , M.
P. H. Fred Hutchinson Cancer Center NCI Cancer Screening Research Network: Coordinating and Communication Center Elyse LeeVan, M.
D. , M. P.
H. Fred Hutchinson Cancer Center Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) Elyse LeeVan, M. D.
, M. P. H.
University Of Oklahoma Hlth Sciences Ctr Oklahoma TRUST Access Hub Elyse LeeVan, M. D. , M.
P. H. Virginia Commonwealth University Virginia Cancer Screening Research Network Access Hub (Virginia CSRN Hub) Elyse LeeVan, M.
D. , M. P.
H. Kaiser Foundation Research Institute Multi-Cancer Early Detection and Screening (MED SCREEN) Study Elyse LeeVan, M. D.
, M. P. H.
Neslund-Dudas, Christine Marie Henry Ford Health + Michigan State University Health Sciences HFH-MSU CSRN ACCrual Enrollment and Screening Site Elyse LeeVan, M. D. , M.
P. H. Univ Of North Carolina Chapel Hill Cancer Screening Research Network - North Carolina Hub (CSRN-NC HUB) Elyse LeeVan, M.
D. , M. P.
H. Siteman Cancer Center Catchment CSRN ACCESS Hub Elyse LeeVan, M. D.
, M. P. H.
Weizmann Institute Of Science Analysis of the predictability of lung cancer using DNA Repair functional assays and cryopreserved blood samples of the PLCO prospective cohort Fred Hutchinson Cancer Center Statistical Methods for Precision Prevention Massachusetts General Hospital Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls University Of Tx Md Anderson Can Ctr Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer SCH: A New Computational Framework for Learning from Imbalanced Biomedical Data
According to the current listing, eligibility includes: University of Colorado Denver and partner institutions; this is a funded cooperative agreement, not an open solicitation. Confirm the full requirements on the funder's own website before applying.
Applications for I-SCREEN (Improving Strategies for Cancer Reduction through Early-detection and ENgagement) are due December 31, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
I-SCREEN (Improving Strategies for Cancer Reduction through Early-detection and ENgagement) is funded by National Cancer Institute (NCI). Verify program details on the funder's own website before applying.
This opportunity targets applicants in Colorado. If your organization operates elsewhere, check the funder's own website for location requirements.
Start from the grants-portal listing linked on this page, then confirm the submission instructions on the funder's own website — the listing is a third-party summary, not the funder's RFP.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleRFA-RM-27-008 funds one or two U24 centers to sequence 6,000-10,000 pediatric samples a year for Gabriella Miller Kids First. Due January 8, 2027. Who can compete.
Read articleProp. 38, the $8.4 billion immunology research bond, led 56% to 44% the morning after the November 3, 2026 election. Here is what the statute says about who can get the grant money, the 20% indirect cap, and the timeline.
Read article